TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05353075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub Occipital Muscle Inhibition
Description: The therapist sits at the head end of the table, palms beneath the subject's head, pads of his fingertips on the posterior arch of the atlas, which will be palpated by the therapist between the external occipital protuberance and the spinous process of the axis vertebra. The therapist locates the gap between the occipital condyles and the spinous phase of the C2 vertebra with the middle and ring fingers of both hands the therapist then rests the base of the skull on his or her hands, with toward the therapist. The pressure will be held at the same level for four minutes until tissue relaxation will be achieved. The subject will be asked to keep his eyes closed during the SMI technique to prevent eye movements disturbing the Sub occipital muscle tone.

Intervention type: OTHER
Group type: OTHER
Intervention: Sub Occipital Muscle Inhibition
Description: The therapist sits at the head end of the table, palms beneath the subject's head, pads of his fingertips on the posterior arch of the atlas, which will be palpated by the therapist between the external occipital protuberance and the spinous process of the axis vertebra. The therapist locates the gap between the occipital condyles and the spinous phase of the C2 vertebra with the middle and ring fingers of both hands the therapist then rests the base of the skull on his or her hands, with toward the therapist. The pressure will be held at the same level for four minutes until tissue relaxation will be achieved. The subject will be asked to keep his eyes closed during the SMI technique to prevent eye movements disturbing the Sub occipital muscle tone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub Occipital Inhibition with Hold Relax Agonist Contraction
Description: Therapist will passively flex the lower extremity with knee extended to the end range of Hip Flexion. Once the end range of motion will attain the patient will apply a 10second isometric force against the therapist manual resistance. After the isometric contraction of hamstring the patient will ask to perform a concentric contraction of opposing muscle (hip flexors) for 10 seconds. As the patient performs the concentric contraction the therapist takes up the slack into any ROM that was gained keeping limb into new stretch position for 10-15 seconds and then rest for 5 seconds. Three repetitions of this technique will be performed on each subject.
Study: NCT05816616

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional imaging of the lungs using MagniXene (hyperpolarized xenon-129) MRI
Description: Patients for this observational study will be selected on a voluntarily basis from the ongoing Airflow-3 interventional clinical trial at Temple University Hospital. For this observational sub-study, patients will have their lung function measured using hyperpolarized xenon-129 MRI prior to TLD treatment, and 90 days post-treatment for a better understanding of treatment effects. This sub-study does not influence in any way the patient treatment or the outcomes for the main Airflow-3 TLD clinical trial.
Study: NCT06047080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive intravenous (IV) glofitamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Participants will receive IV polatuzumab vedotin in combination with R-CHP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polatuzumab vedotin
Description: Participants will receive IV polatuzumab vedotin in combination with R-CHP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive IV rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Participants will receive IV rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide as part of CHP chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide as part of CHP chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive IV doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Participants will receive IV doxorubicin
Study: NCT04687904

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic education
Description: Patients will benefit from a 2-hour interview which will be conducted by the psychologist associated with the project.~The aim of this interview is to help patients better understand their disease in order to adopt the right behaviors on a daily basis. This session will inform patients about their disease, its origins, its treatment, the difficulties it causes and the means to remedy it. The objective of this session is to better understand and manage epilepsy and to enable patients to take an active part in the process of care and management of the disease.~No specific instructions will be given at the end of this interview.
Study: NCT06047080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive oral prednisone as part of CHP chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants will receive oral prednisone as part of CHP chemotherapy
Study: NCT05303532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Fixed dose of 1500 mg via IV infusion upon enrollment visit and every 4 weeks thereafter.
Study: NCT06005428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD-4730
Description: Oral CRD-4730 in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD-4730
Description: Oral CRD-4730 in capsule form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match CRD-4730 in capsule form
Study: NCT04850898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-176
Description: Treatment of influenza

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control
Study: NCT05575011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB115
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB115
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB115
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB115
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB115
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB115
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB115-Matching Placebo
Description: Administered as specified in the treatment arm
Study: NCT06450197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: AZD7798

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06644170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Attend individual visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Therapy
Description: Attend group visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05444465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isolated Bioinductive Repair
Description: Isolated Bioinductive repair with REGENETEN™ Bioinductive Implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Completion and Repair
Description: Standard surgical repair using the 'Completion and Repair' technique.
Study: NCT05088616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Wellness Classes and Medically Tailored Meals
Description: Four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals.
Study: NCT05249101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivaltinostat
Description: Ivaltinostat (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate) is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase (HDAC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).
Study: NCT06352242

Intervention type: OTHER
Group type: OTHER
Intervention: Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients
Description: For each patient, a blood sample will be taken at D0 before the CAR-T cells are injected then at D3, D7, D10, D30 after the injection. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis by effector immune cells (T lymphocytes, NK cells, CAR-T cells) and to define the phenotypic signature of trogocytosis.

Intervention type: OTHER
Group type: OTHER
Intervention: Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers
Description: For each healthy volunteer, a single blood sample will be taken at enrollment. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis of normal lymphocytes and NK cells.
Study: NCT04946942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Healthcare Encounters with Caregivers (CHEC)
Description: CHEC is a brief checklist designed to identify family caregivers' unmet needs and concerns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Attendance at primary care appointments as usual.
Study: NCT05986890

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y Bypass
Description: laparoscopic Roux-en-Y

Intervention type: PROCEDURE
Group type: OTHER
Intervention: gastrojejunostomy
Description: surgical gastrojejunostomy
Study: NCT04373317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimavanserin
Description: Fixed-dose Pimavanserin - Pimavanserin is a new antipsychotic agent, and pure 5HT-2A inverse agonist, that was approved by the FDA recently (2016) for the treatment of PDP. It is the only FDA-approved medication for PDP, but is still not the first-line AP used in PD. All participants assigned to pimavanserin will receive the FDA-approved dose of 34 mg (equivalent to 40 mg pimavanserin tartrate) daily without titration up or down; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability (i.e., overall adverse event profile) and efficacy (i.e., improvement in severity of psychosis).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Flexible-dose Quetiapine - Quetiapine, which is a mixed serotonin and dopamine receptor antagonist, is by far the most commonly used AP for PDP. However, scientific evidence for the efficacy of quetiapine in PDP is almost non-existent as most of the studies were underpowered, had high drop-out rates, and possibly underdosed quetiapine. Quetiapine immediate and extended release will be titrated as shown:~Baseline visit Quetiapine: 25 mg IR QHS, All participants must be up-titrated to 50 mg/day Pimavanserin: 34 mg QHS~Week 1 call Quetiapine: 50 mg XR QHS, Up-titration to 50 mg Pimavanserin: 34 mg QHS~Week 3 visit Quetiapine: 100 mg XR QHS, Up-titration as appropriate Pimavanserin: 34 mg QHS~Week 5 visit Quetiapine: 150 mg XR QHS, Up- or down-titration as appropriate Pimavanserin: 34 mg QHS~Week 6 call Quetiapine: 200 mg XR QHS, Up- or down-titration as appropriate Pimavanserin: 34 mg QHS
Study: NCT04780672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Molixan
Description: The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: Molixan® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
Study: NCT04506931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Survey
Description: Participants will receive a SMS survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVR Survey
Description: Participants will receive an IVR survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CATI Survey
Description: Participants will receive a CATI survey
Study: NCT05930314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNCT19 cell injection
Description: Leukapheresis and manufacturing of CNCT19: enrolled subjects will undergo a leukapheresis to target a yield of \> 1x 10\^9 mononuclear cells~* Lymphodepleting chemotherapy i. Fludarabine 25 to 30 mg/m2, once daily for 3 days ii. Cyclophosphamide 500 mg/m2, once daily for 3 days~* CNCT19 administration i. 0.25 to 0.5 x 10\^8 CAR-positive viable T cells
Study: NCT05419687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Code of conduct delivered via a warning board
Description: A publicly displayed code of conduct (a co-designed set of rules) for both HCWs and clients, delivered via a warning board at the level of the health facilities and secondary hospitals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Code of conduct delivered via a warning board
Description: A publicly displayed code of conduct (a co-designed set of rules) for both HCWs and clients, delivered via a warning board at the level of the health facilities and secondary hospitals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Code of conduct delivered via a warning board
Description: A publicly displayed code of conduct (a co-designed set of rules) for both HCWs and clients, delivered via a warning board at the level of the health facilities and secondary hospitals
Study: NCT05891288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioCoat® by Premier®
Description: Bioactive pits and fissure sealant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3M™ Clinpro™ Sealant.
Description: Fluoride releasing pits and fissure sealant
Study: NCT06568731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: Danuglipron oral tablets
Study: NCT06438159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation with Mindfulness-Based Stress Reduction (MBSR)
Description: The MBSR program is as follows:~* 8 weekly group sessions of 2h30 led by the mindfulness instructor,~* Sessions of around 45 minutes a day to be carried out by the patient, at home, for personal training,~* An intensive day between the 6th and 7th sessions to explore certain practices more intensively, in order to support participants in effectively integrating mindfulness meditation into various life situations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cardiac rehabilitation
Description: The usual cardiac rehabilitation program combines exercise training and therapeutic education workshops, with a daily session for four weeks.
Study: NCT04785300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles
Study: NCT06150404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White Noises and Maternal and/or Paternal voices
Description: The intervention group will receive white noise and maternal and/or paternal voice for a maximum of 4 hours per day, alternated as follows: 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice, 1-hour break, 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice. The intervention is expected to start at 08:00 in the morning and conclude at 13:00 and will be delivered from the day after the enrollment - when the parents provide their voice recording - until the day of discharge.~The device for administering white noise and maternal and/or paternal voice will be placed approximately 30 cm from the head of the infant in the incubator and at the foot of the infant in the open crib.~The volume will be 45 dB for infants in incubators and infants in open cribs.
Study: NCT04105270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Restorative Microbiota Therapy (RMT) Capsules
Description: Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Restorative Microbiota Therapy (RMT) Capsules
Description: Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg IV
Description: Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg IV
Description: Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg IV
Description: Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/pemetrexed or Carboplatin/pemetrexed
Description: Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/pemetrexed or Carboplatin/pemetrexed
Description: Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/pemetrexed or Carboplatin/pemetrexed
Description: Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sixteen doses of oral placebo capsules given weekly
Study: NCT05878717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: .Placebo will be administered.
Study: NCT05738408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives (FI) and Nicotine Replacement Therapy (NRT)
Description: : In the intervention condition, patients will receive both NRT plus a 12-week program of monetary incentives for verified smoking abstinence that will be implemented by our clinic staff
Study: NCT06373263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain-language summary
Description: Participants will receive information about a research study via a plain-language summary. The comparator will be a plain-language summary, since plain-language summaries are commonly used and more easily developed than other tools. The summary will be designed based on Canadian government and other key recommendations, including from the Cochrane Collaboration. It will include Background and Objectives, Methods, Results, Limitations, and Key Message for Patients sections and include information on how evidence informs knowledge or health care options. Abstract will be \< 500 words long and use short, positive, active-voice sentence structures and everyday words. Reading level will be between 8th and 9th grade based on Flesch-Kincaid Grade Level and readability score between 60 and 70 based on Flesch Reading Ease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dissemination Tool (Infographic)
Description: The infographic will be developed based on key principles including clearly defining the audience and purpose; sharing a story, rather than just facts, with brief, clear messaging; highlighting main ideas; using an attractive title and images; and following principles of good graphic design.
Study: NCT06280235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 1569912
Study: NCT05123586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC